FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient t ...
Fulcrum Therapeutics stock surges on Monday after releasing positive results from Phase 1b trial of pociredir in sickle cell ...
Power Technology on MSN
Key themes 2025: what data centres, tariffs and grid bottlenecks mean for the energy transition
Three themes defined the energy industry in 2025: data centres' rising power demand, tariffs disrupting supply chains, and ...
The new year will mean the arrival of more than 20 new state laws limiting extra fees landlords can charge, expanding ...
One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across ...
The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...
10don MSN
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...
Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...
CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback